Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.
You may also be interested in...
Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss
FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.
Acomplia Is "Not Approvable" For Smoking Cessation, "Approvable" For Weight Loss
FDA issued a split decision for Sanofi-Aventis' rimonabant NDAs.
Sanofi May Increase Sales Force Despite Need To Meet Post-Merger Savings Goal
The company says it is on target to achieve its previously announced $2.1 bil. in synergies and is not planning to cut its R&D and promotional budgets to achieve that number. Sanofi-Aventis says Acomplia pre-launch expenses will run into the hundreds of millions of euros.